According to the New York Times, drug manufacturers whose products are not all set for authorization in the United States will shortly receive replies from watchdogs in a new layout meant to a certain extent to prevent alarming financiers.

The Food and Drug Administration will send complex response letters when drugs are not released for sale, more impartial substitutes for the “approvable” or “not approvable” letters employed in the past, the agency announced on Wednesday in a statement on its Web site. Moreover, the changes will commence on August 11.

The organization’s approvable and non-approvable notes leave analysts and investors presuming what suggestion the agency is making regarding a drug’s prospects. The latest system may reduce complaints from companies that say the Food and Drug Administration is lingering when operating on drugs and deluding in its statements about new product submissions. This is the reason why the organization suggested the change to complete response letters in July 2004 and is already using this format for medicines made through biotechnology.

According to the F.D.A., the new letters headed for drug manufacturers will explain what is overlooked in the application and, when viable, offer advice in order to resolve the problem.

However, the new move has already attracted its opponents. For instance, Jon LeCroy, a pharmaceutical analyst at Natixis Bleichroeder in New York, expressed his skepticism regarding the new measures, by saying that investors may be even less enlightened than they are now when companies declare that they have received an approvable or not approvable letter, since the F.D.A. letters are not made public.